Experimental study using heparin-immobilized adsorbent of EDA(+)fibronectin.
EDA(+)fibronectin, which might participate in the pathogenesis and/or progress of immune diseases, is efficiently removed from plasma by cryofiltration; however, cryofiltration removes not only EDA(+)fibronectin, but also other proteins. We thus developed a new adsorbent by using its high affinity with heparin. The purpose of this study was to evaluate the efficacy of the adsorbent of EDA(+)fibronectin (OHC-20) in experimental arthritis. The experimental arthritis was induced by injection of 0.5 mg of Mycobacterium butyricum in Lewis rats. Rats were divided into 4 groups; 1 nontreatment group, and 3 treatment groups. Adsorption therapy in treatment groups was performed three times: on Days 1, 3, and 5 in Group A; Days 7, 9, and 11 in Group B; and Days 13, 15, and 17 in Group C. The walking postures of rats improved from dragging to walking on tiptoe, and the increase of hind-foot volume was suppressed in Groups B and C. We conclude that heparin-immobilized adsorbent might be promising for immune diseases.
Yonekawa
M
M
Research Institute for Artificial Organs, Transplantation, and Gene Therapy, Sapporo Hokuyu Hospital, Japan.
Tanaka
M
M
Kawamura
A
A
Kukita
K
K
Tamaki
T
T
Meguro
J
J
Sakashita
E
E
Sawamoto
M
M
D000327:Adsorption; D000818:Animals; D001169:Arthritis, Experimental / Q000628:therapy*; D005353:Fibronectins / Q000032:analysis*; D006493:Heparin / Q000494:pharmacology*; D051381:Rats; D011917:Rats, Inbred Lew
D005353:Fibronectins; D006493:Heparin